-
-
-
-
-
-
-
ImmunityBio reports survival data from glioblastoma trial
-
-
-
-
-
-
-
ImmunityBio (IBRX) Announces Over 24 Months Median Duration of Complete Remission in Patients with BCG Unresponsive Bladder Cancer
-
-
67,758 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

